Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The transcription factor C/EBPalpha (for CCAAT/enhancer binding protein-alpha; encoded by the gene CEBPA) is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and no mature granulocytes are observed in Cebpa-mutant mice. Here we identify heterozygous mutations in CEBPA in ten patients with acute myeloid leukemia (AML). We found that five mutations in the amino terminus truncate the full-length protein, but did not affect a 30-kD protein initiated further downstream. The mutant proteins block wild-type C/EBPalpha DNA binding and transactivation of granulocyte target genes in a dominant-negative manner, and fails to induce granulocytic differentiation. Ours is the first report of CEBPA mutations in human neoplasia, and such mutations are likely to induce the differentiation block found in AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We have recently shown mutations in the DNA-binding domain of C/EBP␣ in acute myeloid leukemia, suggesting its importance in granulocyte differentiation and leukemia.19”
From Granulocyte inducer C/EBPα inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions (2002) · cites this paper as [19]
Citations
Cites
The scanning model for translation: an update.
Kozak, M. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.2.229 · Cited by 3,486 · cited 1×
“These findings support the concept that CEBPA forms detected with monospecific antibodies are alternative products translated from several in-frame initiation codons by a leaky ribosome-scanning mechanis”
BackgroundThe Leucine Zipper: A Hypothetical Structure Common to a New Class of DNA Binding Proteins
Landschulz, W. H., Johnson, P. F., & McKnight, S. L. (1988) · Science · doi:10.1126/science.3289117 · Cited by 3,443
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Descombes, P., & Schibler, U. (1991) · Cell · doi:10.1016/0092-8674(91)90531-3 · Cited by 990
Isolation of a recombinant copy of the gene encoding C/EBP.
Landschulz, W. H., Johnson, P. F., Adashi, E. Y., Graves, B. J., & McKnight, S. L. (1988) · Genes & Development · doi:10.1101/gad.2.7.786 · Cited by 956
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“In addition, no mature granulocytes are observed in Cebpa -mutant mice, whereas all the other blood cell types are present in normal proportion”
BackgroundSelf-citationTranscription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735 · cited 1×
“gif" NDATA ITEM> ]> Introduction A number of oncogenes that affect proliferation and cell death have been identified in leukemias and other cancers, but relatively few differentiation genes have been implicated in the malignant phenotyp”
BackgroundSelf-citationCCAAT-Enhancer Binding Protein: A Component of a Differentiation Switch
Umek, R. M., Friedman, A. D., & McKnight, S. L. (1991) · Science · doi:10.1126/science.1987644 · Cited by 712 · cited 1×
“bThe abnormalities were one del(9)(q21), one del(9)(q22q34), one t(6;9), one t(10;21)(p11;q22), one del(7)(q22q34), one +8, one +14, and four complex abnormalities.”
BackgroundRadomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T., & Tenen, D. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4301 · Cited by 466 · cited 1×
“cThese patients had a 46,XY,del(12)(p11.”
Self-citation
Cited by
Items 401–500 of 930
Repression of Transcriptional Activity of C/EBPα by E2F-Dimerization Partner Complexes
Zaragoza, K., Bégay, V., Schuetz, A., Heinemann, U., & Leutz, A. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01619-09 · Cited by 38
“The C/EBP gene may mutate to produce oncogenic protein forms that are defective for cell cycle inhibition and that no longer promote cell differentiation (19, 22, 34, 37).”
BackgroundDown-modulation of the C/EBPα transcription factor in core binding factor acute myeloid leukemias
Cilloni, D., Carturan, S., Gottardi, E. M., Messa, F., Messa, E., Fava, M., Diverio, D., Guerrasio, A., Lo‐Coco, F., & Saglio, G. N. (2003) · Blood · doi:10.1182/blood-2003-07-2256 · Cited by 33
Dantas, G. A., Watters, A. L., Lunde, B. M., Eletr, Z. M., Isern, N., Roseman, T., Lipfert, J., Doniach, S., Tompa, M., Kuhlman, B. A., et al. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.07.092 · Cited by 35
Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel
Álvarez, S., & Cigudosa, J. C. (2005) · Hematological Oncology · doi:10.1002/hon.744 · Cited by 37
LaRochelle, O., Bertoli, S., Vergez, F., Sarry, J., Mas, V. M., Dobbelstein, S., Dastugue, N., Strzelecki, A.-C., Cavelier, C., Créancier, L., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.347 · Cited by 37
Matsuo, H., Kajihara, M., Tomizawa, D., Watanabe, T., Saito, A. M., Fujimoto, J., Horibe, K., Kodama, K., Tokumasu, M., Itoh, H., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.47 · Cited by 32
Ahmad, F., Mandava, S., & Das, B. R. (2009) · Hematological Oncology · doi:10.1002/hon.883 · Cited by 32
Gombart, A. F., Grewal, J., & Koeffler, H. P. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0806516 · Cited by 35
for the AML CG study group, Dufour, A. M., Schneider, F., Hoster, E., Benthaus, T., Ksienzyk, B., Schneider, S., Kakadia, P. M., Sauerland, M., Berdel, W. E., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1423-4 · Cited by 35
Self-citationSmith, M. L., Arch, R., Smith, L., Bainton, N. J., Neat, M. J., Taylor, C., Bonnet, D. A., Cavenagh, J. D., Lister, T. A., & Fitzgibbon, J. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05324.x · Cited by 32
“Mutations of KIT, CEBPA and TP53, for example, occur in 5–10% of cases of AML but predominate in patients with ‘favourable’, ‘intermediate’ and ‘poor risk’ cytogenetics respectively (Beghini et al, 2000; Pabst et al, 2001; Stirewalt et al, 2001).”
BackgroundC/EBPα: critical at the origin of leukemic transformation
Roe, J., & Vakoc, C. R. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132530 · Cited by 35
“C/EBP expression can also be down-regulated through direct transcriptional repression by fusion oncoproteins, such as AML1-ETO (Pabst et al., 2001a).”
BackgroundBarnada, S. M., Isopi, A., Tejada-Martínez, D., Goubert, C., Patoori, S., Pagliaroli, L., Tracewell, M., & Trizzino, M. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010225 · Cited by 32
Ahn, J., Kim, J., Kim, H., Kim, Y.-K., Lee, S.-S., Jung, S.-H., Yang, D.-H., Lee, J.-J., Kim, N. Y., Choi, S. H., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2540-7 · Cited by 31
Lidonnici, M. R., Audia, A., Soliera, A. R., di Prisco, M., Ferrari‐Amorotti, G., Waldron, T. J., Donato, N. J., Zhang, Y., Martinez, R. V. P., Holyoake, T. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1667 · Cited by 36
Minimal residual disease testing in hematologic malignancies and solid cancer
Lassoued, A. B., Nivaggioni, V., & Gabert, J. A. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.927311 · Cited by 31
Yang, W., Tsai, W.-C., Lin, P., Yang, M., Liu, Y., Chang, C.-S., Yu, W., & Lin, S.-F. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-58 · Cited by 32
“, FLT3-ITD, FLT3 tyrosine kinase domain (FLT3-TKD) mutation, NPM1 mutation, CEBPA mutation, isocitrate dehydrogenase 1/2 (IDH1/2), DNA (cytosine-5)-methyltransferase 3A (DNMT3A) and mixed lineage leukemia gene (MLL) were screened as previously described [17,24-27].”
Braun, T. P., Coblentz, C., Curtiss, B. M., Coleman, D. J., Schonrock, Z., Carratt, S. A., Callahan, R. L., Maniaci, B. N., Druker, B. J., & Maxson, J. E. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918307117 · Cited by 32
Fioretos, T. (2015) · Wiley eBooks · doi:10.1002/9781118795569.ch8 · Cited by 31
Chattopadhyay, S., Gong, E., Hwang, M., Park, E., Lee, H. J., Hong, C. Y., Choi, H., Cheong, J., Kwon, H. B., & Lee, K. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0240 · Cited by 35
di Prisco, M., Maiorana, A., Guerzoni, C., Calin, G. A., Calabretta, B., Voit, R., Grummt, I., & Baserga, R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5421-5433.2004 · Cited by 33
Tomita, T., Kido, T., Kurotani, R., Iemura, S., Sterneck, E., Natsume, T., Vinson, C., & Kimura, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805140200 · Cited by 30
The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia
O’Connor, C., Lohan, F., Campos, J., Ohlsson, E., Salomè, M., Forde, C., Artschwager, R., Liskamp, R. M. J., Cahill, M. R., Kiely, P. A., et al. (2016) · Oncogene · doi:10.1038/onc.2016.66 · Cited by 31
Zjablovskaja, P., Adamcova, M. K., Daněk, P., Angelisová, P., Benoukraf, T., Wurm, A. A., Kalina, T., Sian, S., Balaštík, M., Delwel, R., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.6 · Cited by 30
Self-citationProteomic discovery of Max as a novel interacting partner of C/EBPα: a Myc/Max/Mad link
Zada, A. A., Pulikkan, J. A., Bararia, D., Geletu, M., Trivedi, A. K., Balkhi, M. Y., Hiddemann, W., Tenen, D. G., Behre, H. M., & Behre, G. (2006) · Leukemia · doi:10.1038/sj.leu.2404438 · Cited by 34
Self-citationShih, L., Huang, C., Lin, T., Wu, J., Wang, P., Dunn, P., Kuo, M., & Tang, T. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1932 · Cited by 31
“The PCR reaction was done in a mixture containing 100 ng genomic DNA, 200 Amol/L deoxynucleotide triphosphate, 1 Gold PCR buffer, and 1 unit AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA), with two overlapping pairs of primers: PP1F 5V-TCGCCATGCCGGGAGAACTCTAAC-3V and PP1R 5V-CTGGTAAGGGAAGAGGCCGGCCAG -3…”
BackgroundMethodInfluentialExpression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia
Müller‐Tidow, C., Metzelder, S., Buerger, H., Packeisen, J., Ganser, A., Heil, G., Kügler, K., Adigüzel, G., Schwäble, J., Steffen, B., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403296 · Cited by 33
Re-envisioning genetic predisposition to childhood and adolescent cancers
Kratz, C. P. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00775-7 · Cited by 31
Dynamics of epigenetic modifications in leukemia
Uribesalgo, I., & Croce, L. D. (2011) · Briefings in Functional Genomics · doi:10.1093/bfgp/elr002 · Cited by 33
“role in controlling myeloid differentiation [57, 58].”
Yang, L., Liu, Y., Zhang, N., Ding, X., Zhang, W., Shen, K., Huang, L., Zhou, J., Cui, S., Zhu, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16449 · Cited by 34
Updates in molecular genetics of acute myeloid leukemia
Kurzer, J. H., & Weinberg, O. K. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.04.002 · Cited by 33
RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT–enhancer binding protein α function
Tokita, K., Maki, K., & Mitani, K. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00597.x · Cited by 35
Röhrs, S., Scherr, M., Romani, J., Zaborski, M., Drexler, H. G., & Quentmeier, H. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-15 · Cited by 30
C/EBPα Is Required for Proteolytic Cleavage of Cyclin A by Calpain 3 in Myeloid Precursor Cells
Welm, A. L., Timchenko, N. A., Ono, Y., Sorimachi, H., Radomska, H. S., Tenen, D. G., Lekstrom-Himes, J. A., & Darlington, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204096200 · Cited by 30
Self-citationThe Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis
Kishtagari, A., & Levine, R. L. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034975 · Cited by 33
“This pattern of mutations produces p30/p30 homodimers as the functional CEBPA transcription factor entity in CEBPA-mutant AML (Pabst et al. 2001; Kirstetter et al. 2008).”
BackgroundGhanem, H., Tank, N., & Tabbara, I. A. (2011) · American Journal of Hematology · doi:10.1002/ajh.22197 · Cited by 28
Regalo, G., Resende, C., Wen, X., Gomes, B., Durães, C., Seruca, R., Carneiro, F., & Machado, J. C. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.79 · Cited by 28
Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis
Bustamante, O. Q., Smith, S. L.-L., Griessinger, E., Reyal, Y., Vargaftig, J., Lister, T. A., Fitzgibbon, J., & Bonnet, D. A. (2012) · Leukemia · doi:10.1038/leu.2012.38 · Cited by 32
Kandilci, A., & Grosveld, G. C. (2009) · Blood · doi:10.1182/blood-2009-02-205443 · Cited by 28
Debeljak, M., Kitanovski, L., Pajič, T., & Jazbec, J. (2013) · Haematologica · doi:10.3324/haematol.2012.082578 · Cited by 28
Wang, L., Yao, Q., Guo, X., Wang, B., Si, J., Wang, X., Jing, S., Yan, M., Shi, Y., Song, G., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02665-4 · Cited by 27
Fasan, A., Alpermann, T., Haferlach, C., Grossmann, V., Roller, A., Kohlmann, A., Eder, C., Kern, W., Haferlach, T., & Schnittger, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054365 · Cited by 29
“Mutations in the CEBPA gene have been described for approximately 5–10% of all AML patients and are most common in CN-AML (15%) [2,3].”
BackgroundSelf-citationLabouré, G., Dulucq, S., Labopin, M., Tabrizi, R., Guérin, E., Pigneux, A., Lafarge, X., Leguay, T., Bouabdallah, K. K., Dilhuydy, M., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.06.012 · Cited by 27
Kawano, Y., Nasu, K., Hijiya, N., Tsukamoto, Y., Amada, K., Abe, W., Kai, K., Moriyama, M., & Narahara, H. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1608 · Cited by 28
Serrano, E., Carnicer, M. J., Orantes, V., Estivill, C., Lasa, A., Brunet, S., Aventin, A. M., Sierra, J., & Nomdedeu, J. F. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802035941 · Cited by 27
Maun, N. A., Gaines, P. C. W., Khanna‐Gupta, A., Zibello, T., Enriquez, L., Goldberg, L., & Berliner, N. (2003) · Blood · doi:10.1182/blood-2002-10-3247 · Cited by 27
Cheng, D. T., Cheng, J., Mitchell, T. N., Syed, A., Zehir, A., Mensah, N. Y. T., Oultache, A., Nafa, K., Levine, R. L., Arcila, M. E., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.05.006 · Cited by 26
Bonifer, C., & Bowen, D. T. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001377 · Cited by 26
Molecular characterization of acute myeloid leukemia and its impact on treatment
Frankfurt, O., Licht, J. D., & Tallman, M. S. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f10e55 · Cited by 34
Humbert, M., Federzoni, E. A., Britschgi, A., Schläfli, A. M., Valk, P. J. M., Kaufmann, T., Haferlach, T., Behre, G., Simon, H., Torbett, B. E., et al. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1112608 · Cited by 30
Self-citationMori, Y., Yoshimoto, G., Kumano, T., Miyamoto, T., Iino, T., Takenaka, K., Iwasaki, H., Harada, N., Kinukawa, N., Nagafuji, K., et al. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00866.x · Cited by 26
Kim, J., Ogata, Y., & Feldman, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212118200 · Cited by 27
Yang, W., Lin, P., Yang, M., Liu, Y., Chang, C.-S., Chou, W., Hsu, J.-F., Huang, C.-T., Cho, S., Yu, W., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.749402 · Cited by 26
Insight into the molecular pathogenesis of myeloid malignancies
Haferlach, T., Bacher, U., Haferlach, C., Kern, W., & Schnittger, S. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3280168490 · Cited by 26
Self-citationMatsushita, H., Nakajima, H., Nakamura, Y., Tsukamoto, H., Tanaka, Y., Gui-lan, J., Yabe, M., Asai, S., Ono, R., Nosaka, T., et al. (2008) · Oncogene · doi:10.1038/onc.2008.285 · Cited by 27
Nerlov, C. (2010) · BioEssays · doi:10.1002/bies.201000004 · Cited by 25
Porse, B. T., Pedersen, T. Å., Hasemann, M. S., Schuster, M. B., Kirstetter, P., Luedde, T., Damgaard, I., Kurz, E., Schjerling, C. K., & Nerlov, C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.1028-1037.2006 · Cited by 27
Bench, A. J., Erber, W. N., & Scott, M. A. (2005) · Clinical & Laboratory Haematology · doi:10.1111/j.1365-2257.2005.00701.x · Cited by 28
Clonal conversion of B lymphoid leukemia reveals cross-lineage transfer of malignant statesPreprint
Somasundaram, R., Åhsberg, J., Okuyama, K., Ungerbäck, J., Lilljebjörn, H., Fioretos, T., Strid, T., & Sigvardsson, M. (2016) · Genes & Development · doi:10.1101/gad.285536.116 · Cited by 26
“2015); however, because C/ EBP proteins may act as tumor suppressors (Pabst et al. 2001; Nerlov 2004), continued ectopic expression of C/ EBP proteins from the retroviral insertionsmight counteract the formation of myeloid leukemia.”
BackgroundResultKurt, H., Jorgensen, J. L., Amin, H. M., Patel, K. P., Wang, S. A., Lin, P., Kanagal‐Shamanna, R., Loghavi, S., Thakral, B., Khogeer, H. A., et al. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13038 · Cited by 24
Aberrant DNA methylation of the transcription factor C/EBPα in acute myelogenous leukemia
Jost, E., do Ó, N., Wilop, S., Herman, J. G., Osieka, R., & Galm, O. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.07.027 · Cited by 24
“C/EBPα mutations may ontribute to the loss of normal protein function by nonsense utations in the 5′ region of the gene or amino acid substiution in functionally important domains [4,5].”
BackgroundThe challenge of risk stratification in acute myeloid leukemia with normal karyotype
Zaidi, S. Z. A., Owaidah, T. M., Sharif, F. A., Ahmed, S. Y., Chaudhri, N. A., & Aljurf, M. D. (2008) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/s1658-3876(08)50023-9 · Cited by 24
Dominant-interfering C/EBPα stimulates primitive erythropoiesis in zebrafish
Liu, T. X., Rhodes, J., Deng, M., Hsu, K., Radomska, H. S., Kanki, J. P., Tenen, D. G., & Look, A. T. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2006.10.008 · Cited by 25
Self-citationInterfering with Cancer: A Brief Outline of Advances in RNA Interference in Oncology
Rye, P. D., & Stigbrand, T. I. (2004) · Tumor Biology · doi:10.1159/000081403 · Cited by 24
Heyes, E. C., Schmidt, L., Manhart, G., Eder, T., Proietti, L., & Grebien, F. (2021) · Leukemia · doi:10.1038/s41375-021-01169-6 · Cited by 24
Faulk, K. E., Gore, L., & Cooper, T. M. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0067-3 · Cited by 26
MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML
Sauer, T., Arteaga, M. F., Isken, F., Rohde, C., Hebestreit, K., Mikesch, J., Stelljes, M., Cui, C., Zhou, F., Göllner, S., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.010 · Cited by 24
Regalo, G., & Leutz, A. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302834 · Cited by 25
“…of the of GATA1 or C/EBP a N ‐ termini are connected to leukaemogenesis, suggesting balanced and context speci fi c functions in homeostasis and calling into attention the relation between lineage specifying factor dysregulation and disease (DeKoter & Singh, 2000; Ge et al, 2006; Pabst et al, 2001).”
Ramberger, E., Sapozhnikova, V., Kowenz‐Leutz, E., Zimmermann, K., Nicot, N., Nazarov, P. V., Pérez-Hernández, D., Reimer, U., Mertins, P., Dittmar, G., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102686 · Cited by 25
Role of the RUNX1‐EVI1 fusion gene in leukemogenesis
Maki, K., Yamagata, T., & Mitani, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00956.x · Cited by 27
Mitochondrial targeting signal in human neuropeptide Y gene
Kaipio, K., Kallio, J., & Pesonen, U. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.093 · Cited by 24
Gocek, E., & Studzinski, G. P. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040504 · Cited by 23
“normal AMLs [114,120].”
BackgroundThompson, E. A., Zhu, S., Hall, J. R., House, J. S., Ranjan, R., Burr, J. A., He, Y., Owens, D. M., & Smart, R. C. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.31 · Cited by 22
“C/EBPa has been established as a tumor-suppressor gene in human acute myeloid leukemia (Pabst et al., 2001).”
BackgroundPten regulates homeostasis and inflammation-induced migration of myelocytes in zebrafish
Dong, Z., Ren, C., Xia, Y. Q., Su, D., Du, T., Fan, H.-B., Yuan, H., Wang, L., Dong, M., Li, W., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-17 · Cited by 23
“and mutations in CEBPA are widely reported in acute myeloid leukemia (AML) patients [13-16].”
BackgroundOdenike, O. M., Thirman, M. J., Artz, A. S., Godley, L. A., Larson, R. A., & Stock, W. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.010 · Cited by 27
Liu, M., Du, M., Yu, J., Qian, Z., Gao, Y., Pan, W., Zhao, X., Wang, M., Li, H., Zheng, J., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2016158 · Cited by 22
Smith, M. L., & McKerrell, T. (2016) · Wiley eBooks · doi:10.1002/9781118527948.ch3 · Cited by 22
Costa, D. B., Li, S., Kocher, O. N., Feins, R. H., Keller, S. M., Schiller, J. H., Johnson, D. H., Tenen, D. G., & Halmos, B. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2006.11.023 · Cited by 24
“The association of C/ EBPα and cancer has been elucidated in acute myeloid leukemia (AML) (19), where C/ EBPα expression is reduced in leukemias carrying the t(8;21) translocation (20) and C/ EBPα mutations confer improved prognosis in a small subgroup of AML patients with normal cytogenetics (21,22).”
BackgroundSelf-citationHaas, S. C., Huber, R., Gutsch, R., Kandemir, J. D., Cappello, C., Krauter, J., Duyster, J., Ganser, A., & Brand, K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08012.x · Cited by 24
“It has been suggested that the transcription factor C/EBPb, belonging to the C/EBP family, plays a crucial role in malignant disease (Ramji & Foka, 2002; Jundt et al, 2005), similar to its relative C/EBPa (Pabst et al, 2001; Rosenbauer & Tenen, 2007).”
BackgroundAhmad, F., Mandava, S., & Das, B. R. (2009) · Cancer Investigation · doi:10.1080/07357900903095649 · Cited by 22
Emerging Flt3 kinase inhibitors in the treatment of leukaemia
Tickenbrock, L., Müller‐Tidow, C., Berdel, W. E., & Serve, H. L. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.1.153 · Cited by 22
“1 and c/EBP-α are found be mutated in a significant proportion of AML patients [66,67].”
BackgroundGatekeeper pathways and cellular background in the pathogenesis and therapy of AML
Cammenga, J. (2005) · Leukemia · doi:10.1038/sj.leu.2403894 · Cited by 27
A leukemogenic twist for GATA1
Look, A. T. (2002) · Nature Genetics · doi:10.1038/ng960 · Cited by 22
Adamo, A., Chin, P. S., Keane, P., Assi, S. A., Potluri, S., Kellaway, S. G., Coleman, D., Ames, L., Ptasinska, A., Delwel, R., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01744-5 · Cited by 23
Smith, L., Pearce, D., Smith, M. L., Jenner, M., Lister, T. A., Bonnet, D. A., Goff, L. K., & Fitzgibbon, J. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06001.x · Cited by 21
“Many of these mutations result in the insertion or deletion of a small number of additional nucleotides that should allow for the design of a specific primer against the unique sequence generated by the mutation (Pabst et al, 2001).”
BackgroundVerhaak, R. G. W., & Valk, P. J. M. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-69259-3_5 · Cited by 21
Yin, H., Radomska, H. S., Tenen, D. G., & Glass, J. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-158 · Cited by 24
“In other patients with morphologically similar leukemias, but without the t(8;21) translocation, heterozygous mutations in C/EBPα result in the production of an amino terminus truncated protein that acts in a dominant negative manner to block C/EBPα DNA binding [2].”
InfluentialSelf-citationDecitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases
Jiang, H., Wu, Z., REN, L., Tao, D., & Tong, H. (2015) · Oncology Letters · doi:10.3892/ol.2015.3977 · Cited by 21
Fukuchi, Y., Ito, M., Shibata, F., Kitamura, T., & Nakajima, H. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0320 · Cited by 20
Affinity Purification Strategies for Proteomic Analysis of Transcription Factor Complexes
Giambruno, R., Grebien, F., Stukalov, A., Knöll, C., Planyavsky, M., Rudashevskaya, E. L., Colinge, J., Superti‐Furga, G., & Bennett, K. L. (2013) · Journal of Proteome Research · doi:10.1021/pr4003323 · Cited by 20
Na+/H+ exchanger 1 inhibition contributes to K562 leukaemic cell differentiation
Jin, W., Li, Q., Wang, J., Chang, G., Lin, Y., Li, H., Wang, L., Gao, W. Q., & Pang, T. (2012) · Cell Biology International · doi:10.1042/cbi20100919 · Cited by 20
“Mutations of C/EBPa in AML and down-modulation of C/EBPa in CML-BC patient samples have been reported, which indicate that novel therapeutic approaches targeted to C/EBPa can be helpful for the prognosis of haemopoietic cell malignancy (Pabst et al., 2001; Tavor et al., 2003).”
BackgroundMolecular diagnosis of acute myeloid leukemia
Watt, C. D., & Bagg, A. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.85 · Cited by 22
van der Valk, M. A., Delwel, R., Wouters, B. J., Löwenberg, B., Erpelinck-Verschueren, C. A. J., van Putten, W. L. J., & Peter, J. M. (2009) · Cited by 20
Kwon, H., Jang, D., Choi, M., Lee, J. W., Jeong, K., & Pak, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.022 · Cited by 20
C/EBPαp30 plays transcriptional regulatory roles distinct from C/EBPαp42
Wang, C., Chen, X., Wang, Y., Gong, J., & Hu, G. (2007) · Cell Research · doi:10.1038/sj.cr.7310121 · Cited by 23
Yin, H., Lowery, M. N., & Glass, J. (2009) · The Prostate · doi:10.1002/pros.20947 · Cited by 22
Yin, H., & Glass, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511138200 · Cited by 22
Ectopic expression of C/EBPα in the lung epithelium disrupts late lung development
Berg, T., Didon, L., & Nord, M. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00497.2005 · Cited by 20
The Cell Biology of Stem Cells
Meshorer, E., & Plath, K. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-7037-4 · Cited by 23
Carmichael, C., Wilkins, E. J., Bengtsson, H. L., Horwitz, M. S., Speed, T. P., Vincent, P. C., Young, G. A. R., Hahn, C. N., Escher, R., & Scott, H. S. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08204.x · Cited by 20
“…has been identified in up to 14% of patients with sporadic acute myeloid leukaemia (AML), and germline mutations have been reported in several families with autosomal dominant inheritance of AML and eosinophilia (Pabst et al, 2001; Gombart et al, 2002; Smith et al, 2004; Sellick et al, 2005).”
Background
Metadata
- Authors
- Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Genetics
- Published
- 2001-03
- Volume
- 27
- Issue
- 3
- Pages
- 263-270
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2100088478
- Cited by
- 901
- References
- 33
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 23 · 2023: 21 · 2022: 30 · 2021: 22 · 2020: 27 · 2019: 17 · 2018: 22 · 2017: 27 · 2016: 29 · 2015: 47 · 2014: 37 · 2013: 34 · 2012: 50
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- CEBPA, C/EBPα, acute myeloid leukemia, dominant negative mutation, heterozygous mutation, transcription factors, granulocytic differentiation, DNA binding, transcriptional activation, N-terminal truncation
- MeSH terms
- Base Sequence, Cell Differentiation, Cell Nucleus, DNA, Neoplasm, Genes, Dominant, Granulocytes, Heterozygote, Humans, Mutation, Neutrophils, Leukemia, Myeloid, Acute, Transcriptional Activation, Sequence Deletion, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.